The Effects of Drugs on CYP3A Enzyme Activity and Protein Expression Through Ubiquitination Modification Regulation
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70102 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Fang Wang and 7 co-authors. Institution: Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China. Major MEDLINE topics: Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inhibitors, Hypoxia. 46 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Natural Science Foundation of China, Heilongjiang Natural Science Foundation Joint Guidance Project.
Abstract (original language)
Cytochrome P450 3A4 (CYP3A4) is one of the most important members of the cytochrome P450 subfamily, which is involved in the catalytic process of many drug activation or deactivation. Meanwhile, it is also a risk factor for drug‐induced toxic reactions. Our research investigates the impact of drugs on CYP3A4 enzyme activity and protein expression, and that CYP3A4 inhibition induced by drugs may exacerbate under hypoxia. Molecular docking has found that the drug has binding sites with amino acid residues in the active region of CYP3A4, which may affect the ability of the CYP3A4 enzyme to metabolize drugs. Twenty male Sprague Dawley rats were divided into two groups: control (FiO 2 : 21%), hypoxia (FiO 2 : 10%) for 14 days. Liver microsomes from hypoxic and normoxic rats were used for in vitro experiments by high‐performance liquid chromatography. Drug concentration in blood in vivo was measured by LC–MS/MS. Further studies have revealed that drugs mediate the degradation of CYP3A4 ubiquitination‐proteasome pathway through E3 ubiquitin ligase gp78 by immunoprecipitation, which may exacerbate the CYP3A4 inhibition under hypoxic conditions. These elucidated that the inhibition of CYP3A4 may worsen under pathological conditions (such as hypoxia), providing a basis for rational clinical medication to reduce or avoid drug interactions and toxic reactions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
- Department of Ophthalmology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.
ORCID profiles: Baoxin Li
Funding
- National Natural Science Foundation of China
- Heilongjiang Natural Science Foundation Joint Guidance Project
Cite
APA
Wang, F., Gu, X., Hong, H., Xia, Q., Zhang, Y., Song, Y., Li, B., & Fan, P. (2025). The Effects of Drugs on CYP3A Enzyme Activity and Protein Expression Through Ubiquitination Modification Regulation. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70102
Vancouver
Wang F, Gu X, Hong H, Xia Q, Zhang Y, Song Y, et al. The Effects of Drugs on CYP3A Enzyme Activity and Protein Expression Through Ubiquitination Modification Regulation. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70102
BibTeX
@article{Wang2025,
author = {Wang, Fang and Gu, Xiwei and Hong, Haiying and Xia, Qianqian and Zhang, Yuxin and Song, Ying and Li, Baoxin and Fan, Pan},
title = {The Effects of Drugs on CYP3A Enzyme Activity and Protein Expression Through Ubiquitination Modification Regulation},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70102}
}
EUVIMED